eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hypercalcemia |
| Comorbidity | C0026764|multiple myeloma |
| Sentences | 7 |
| PubMedID- 25128013 | Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. |
| PubMedID- 21915243 | Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors [21]–[26]. |
| PubMedID- 24743202 | Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers. |
| PubMedID- 24334568 | It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients. |
| PubMedID- 21605111 | Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma. |
| PubMedID- 22073517 | multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis. |
| PubMedID- 22082730 | Introduction: osteonecrosis of the jaw (onj) is an emerging condition in patients undergoing long-term administration of bisphosphonates (bp) for the treatment of osteoporosis and hypercalcaemia associated with malignancy, multiple myeloma, and metastatic breast and prostate cancers. |
Page: 1